Interferon Alpha-2: Pre-Clinical and Clinical Evaluation

Proceedings of the Symposium held in Adjunction with the Second International Conference on Malignant Lymphoma, Lugano, Switzerland, June 13, 1984

Nonfiction, Health & Well Being, Medical, Specialties, Oncology
Cover of the book Interferon Alpha-2: Pre-Clinical and Clinical Evaluation by , Springer US
View on Amazon View on AbeBooks View on Kobo View on B.Depository View on eBay View on Walmart
Author: ISBN: 9781461325796
Publisher: Springer US Publication: December 6, 2012
Imprint: Springer Language: English
Author:
ISBN: 9781461325796
Publisher: Springer US
Publication: December 6, 2012
Imprint: Springer
Language: English

Interferon alpha-2 is a genetically engineered, highly purified pharmaceutical agent that has undergone extensive phase I and phase II clinical study in more than 1000 patients. The material has biological activity by intravenous, intramus­ cular and subcutaneous routes. Clinical toxicity principally involves the 'influen­ za like' syndrome previously seen with native interferons. Other important toxi­ cities include anorexia, hepatitis, confusion and myelosuppression. Tolerable doses in multiple schedules and routes of administration have been determined. Phase II clinical trials with multiple routes and schedules of administration have been performed. Significant clinical activity has been found in non­ Hodgkin's lymphomas (both low grade and high grade), refractory and relapsing multiple myeloma, hairy cell leukemia, Kaposi's sarcoma, with suggestions of activity in Hodgkin's disease, renal cell carcinoma, and melanoma. The studies performed to date have for the most part involved small numbers of heavily pre-treated patients. Large-scale clinical trials in some of these disea­ ses are now warranted in populations of patients with as little bulk disease and prior treatment as is feasible for each tumour type. This is particularly the case in . Hodgkin's disease and subcategories of the non-Hodgkin's lymphomas. Alterna­ tely, interferon alpha-2 might be used to maintain remissions induced by other modalities (i. e. , in NHL, multiple myeloma, ovarian cancer). In some advanced disease settings, combinations of interferon alpha-2 with chemotherapeutic agents should now be investigated.

View on Amazon View on AbeBooks View on Kobo View on B.Depository View on eBay View on Walmart

Interferon alpha-2 is a genetically engineered, highly purified pharmaceutical agent that has undergone extensive phase I and phase II clinical study in more than 1000 patients. The material has biological activity by intravenous, intramus­ cular and subcutaneous routes. Clinical toxicity principally involves the 'influen­ za like' syndrome previously seen with native interferons. Other important toxi­ cities include anorexia, hepatitis, confusion and myelosuppression. Tolerable doses in multiple schedules and routes of administration have been determined. Phase II clinical trials with multiple routes and schedules of administration have been performed. Significant clinical activity has been found in non­ Hodgkin's lymphomas (both low grade and high grade), refractory and relapsing multiple myeloma, hairy cell leukemia, Kaposi's sarcoma, with suggestions of activity in Hodgkin's disease, renal cell carcinoma, and melanoma. The studies performed to date have for the most part involved small numbers of heavily pre-treated patients. Large-scale clinical trials in some of these disea­ ses are now warranted in populations of patients with as little bulk disease and prior treatment as is feasible for each tumour type. This is particularly the case in . Hodgkin's disease and subcategories of the non-Hodgkin's lymphomas. Alterna­ tely, interferon alpha-2 might be used to maintain remissions induced by other modalities (i. e. , in NHL, multiple myeloma, ovarian cancer). In some advanced disease settings, combinations of interferon alpha-2 with chemotherapeutic agents should now be investigated.

More books from Springer US

Cover of the book The Future of Piagetian Theory by
Cover of the book The Social Construction of Trust by
Cover of the book Organic Additives and Ceramic Processing by
Cover of the book The Determinants of Economic Growth by
Cover of the book Surgical Intensive Care Medicine by
Cover of the book Metacognition by
Cover of the book Health Psychology by
Cover of the book Designing Competitive Electricity Markets by
Cover of the book Knowledge Acquisition for Expert Systems by
Cover of the book Ethics in Community Mental Health Care by
Cover of the book Technological Systems in the Bio Industries by
Cover of the book Genitourinary Cancer by
Cover of the book Nutrition and Feeding of Fish by
Cover of the book Electrodermal Activity by
Cover of the book Cryopreservation and low temperature biology in blood transfusion by
We use our own "cookies" and third party cookies to improve services and to see statistical information. By using this website, you agree to our Privacy Policy